BDXTICKER
Becton Dickinson & Co.
Congress has disclosed 39 buys and 33 sells of BDX (Becton Dickinson & Co.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
39
Buy
33
Sell
+6
Net
28
Active politicians
Round-trip watch Still on the books
Members who disclosed buying BDX and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Thomas Kean | 2025-05-13 | $132.95 | $197.88 | +48.8% | in profit |
| Alan Armstrong | 2026-03-27 | $152.53 | $197.88 | +29.7% | in profit |
| Rohit Khanna | 2026-09-11 | $177.85 | $197.88 | +11.3% | in profit |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Price & congressional trades
Buy
Sell
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
P/E
57.28
▲ pricier than
Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$197.88 ÷ $3.45 = 57.28
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
2.21
▼ cheaper than
Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$197.88 ÷ $89.64 = 2.21
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
15.67
≈ in line with
Health (median 16.2)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA
($53.9B + $16.1B net debt) ÷ $4.5B = $70.0B ÷ $4.5B = 15.67
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
72 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2026-09-11 | 20 days | +0.1% | $1K–$15K | 54.6 | ↗ filing |
| Thomas Kean | House | SELL ◆ insider convergence | Self · Kean Family Partnership | 2026-05-21 | 12 days | -1.2% | $1K–$15K 0.1% of NW |
67.4 | ↗ filing |
| Alan Armstrong | Senate | BUY ◆ insider divergence | Self | 2026-03-27 | 116 days | +0.3% | $1K–$15K | 99.1 | ↗ eFD |
| Kevin Hern | House | SELL ◆ insider convergence | Joint · Hern Family Revocable Trust | 2026-03-17 | 14 days | -2.7% | $15K–$50K 0.4% of NW |
88.7 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider convergence · moderate | Child | 2025-09-29 | 3 days | +4.1% | $1K–$15K | 4.0 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider divergence · moderate | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-24 | 50 days | +14.2% | $1K–$15K 0.1% of NW |
84.7 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider convergence · moderate | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-17 | 57 days | +15.3% | $1K–$15K 0.1% of NW |
98.1 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2025-05-19 | 21 days | -2.0% | $1K–$15K | 32.6 | ↗ filing |
| Rob Bresnahan | House | BUY ◆ insider divergence | Self · JP Morgan Brokerage Account | 2025-05-15 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
51.1 | ↗ filing |
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2025-05-13 | 23 days | -2.5% | $1K–$15K 0.1% of NW |
88.4 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2025-04-21 | 17 days | -14.6% | $1K–$15K | 12.3 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2025-04-17 | 21 days | -15.5% | $1K–$15K | 13.4 | ↗ filing |
| Rob Bresnahan | House | SELL ◆ insider divergence · moderate | Self · JP Morgan Brokerage Account | 2025-04-08 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
67.0 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider divergence · moderate | Child | 2025-04-07 | 31 days | -18.1% | $1K–$15K | 14.3 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider divergence · moderate | Child | 2025-04-04 | 34 days | -19.0% | $1K–$15K | 28.4 | ↗ filing |
| Jefferson Shreve | House | SELL ◆ insider divergence · moderate | Self · CRT - Standard Unit Trust | 2025-03-05 | 23 days | +2.0% | $15K–$50K <0.1% of NW |
84.7 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-12-06 | 32 days | +6.0% | $1K–$15K | 8.6 | ↗ filing |
| John James | House | SELL | Self · John A. James Children’s Trust | 2024-09-04 | 1 days | -1.3% | $1K–$15K <0.1% of NW |
84.6 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-05-29 | 6 days | — | $1K–$15K | 19.6 | ↗ filing |
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2024-05-24 | 10 days | — | $1K–$15K 0.1% of NW |
89.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-03-25 | 9 days | — | $1K–$15K | 15.7 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-03-21 | 13 days | — | $1K–$15K | 22.3 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-02-13 | 21 days | — | $1K–$15K | 40.4 | ↗ filing |
| Thomas Kean | House | BUY ◆ insider divergence | Self · Kean Family Partnership | 2024-01-11 | 22 days | — | $1K–$15K 0.1% of NW |
97.3 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2023-12-05 | 30 days | — | $1K–$15K | 75.9 | ↗ filing |
| John James | House | BUY ◆ insider divergence | Self · John A. James Children’s Trust | 2023-11-10 | 277 days | — | $1K–$15K <0.1% of NW |
98.8 | ↗ filing |
| Greg Stanton | House | SELL ◆ insider convergence | Spouse | 2023-10-24 | 2 days | — | $1K–$15K 0.5% of NW |
40.4 | ↗ filing |
| Greg Stanton | House | BUY ◆ insider divergence | Spouse | 2023-09-26 | 25 days | — | $1K–$15K 0.5% of NW |
75.9 | ↗ filing |
| Zoe Lofgren | House | SELL | Spouse · John Marshall Collins Rollover IRA | 2023-05-25 | 12 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Zoe Lofgren | House | BUY | Spouse · John Marshall Collins Rollover IRA | 2022-09-09 | 32 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Kim Schrier | House | SELL | Joint | 2021-10-28 | 1 days | — | $1K–$15K <0.1% of NW |
99.0 | ↗ filing |
| John Curtis | House | SELL | Self | 2021-06-22 | 9 days | — | $1K–$15K | 40.4 | ↗ filing |
| Marjorie Taylor Greene | House | BUY | Joint | 2021-05-12 | 0 days | — | $1K–$15K | 75.9 | ↗ filing |
| Kevin Hern | House | SELL | Joint | 2020-11-19 | 1 days | — | $1K–$15K 0.1% of NW |
94.6 | ↗ filing |
| David McKinley | House | SELL | Joint | 2020-08-25 | 6 days | — | $15K–$50K | 19.1 | ↗ filing |
| Robert Wittman | House | SELL | Self | 2020-05-22 | 5 days | — | $1K–$15K 0.2% of NW |
40.4 | ↗ filing |
| David McKinley | House | BUY | Joint | 2020-04-30 | 0 days | — | $1K–$15K | 18.1 | ↗ filing |
| David McKinley | House | BUY | Self | 2020-04-30 | 0 days | — | $1K–$15K | 18.1 | ↗ filing |
| Kevin Hern | House | BUY | Joint | 2020-04-09 | 1 days | — | $1K–$15K 0.1% of NW |
99.7 | ↗ filing |
| John Curtis | House | BUY | Self | 2020-03-27 | 0 days | — | $1K–$15K | 86.8 | ↗ filing |
| Cindy Axne | House | SELL | Self | 2020-03-09 | 567 days | — | $1K–$15K | 31.8 | ↗ filing |
| Cindy Axne | House | SELL | Spouse | 2020-03-09 | 567 days | — | $1K–$15K | 31.8 | ↗ filing |
| Mikie Sherrill | House | SELL | Self | 2020-02-20 | 12 days | — | $1K–$15K 0.1% of NW |
86.8 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2019-11-07 | 27 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Elizabeth Fletcher | House | SELL | Spouse | 2019-07-09 | 3 days | — | $1K–$15K 0.2% of NW |
93.6 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2019-06-12 | 28 days | — | $1K–$15K <0.1% of NW |
52.4 | ↗ filing |
| Cindy Axne | House | BUY | Spouse | 2019-04-23 | 888 days | — | $1K–$15K | 86.8 | ↗ filing |
| Cindy Axne | House | BUY | Self | 2019-04-23 | 888 days | — | $1K–$15K | 86.8 | ↗ filing |
| Michael Conaway | House | BUY | Spouse | 2019-04-18 | 5 days | — | $1K–$15K | 52.4 | ↗ filing |
| Elizabeth Fletcher | House | SELL | Spouse | 2019-02-26 | 52 days | — | $1K–$15K 0.2% of NW |
94.6 | ↗ filing |
| Elizabeth Fletcher | House | SELL | Self | 2019-02-07 | 74 days | — | $1K–$15K 0.2% of NW |
98.8 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2019-02-05 | 17 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-01-04 | 32 days | — | $1K–$15K <0.1% of NW |
86.8 | ↗ filing |
| David McKinley | House | BUY | Self | 2018-12-20 | 11 days | — | $1K–$15K | 31.0 | ↗ filing |
| David McKinley | House | SELL | Joint | 2018-12-19 | 12 days | — | $15K–$50K | 30.7 | ↗ filing |
| Michael Conaway | House | BUY | Spouse | 2018-11-21 | 5 days | — | $1K–$15K | 86.8 | ↗ filing |
| Thomas Rooney | House | SELL | Self | 2017-09-22 | 9 days | — | $1K–$15K | 15.7 | ↗ filing |
| David McKinley | House | BUY | Self | 2017-09-14 | 16 days | — | $1K–$15K | 22.3 | ↗ filing |
| Carlos Curbelo | House | SELL | Spouse | 2017-04-05 | 41 days | — | $1K–$15K | 52.4 | ↗ filing |
| Mo Brooks | House | SELL | Joint | 2017-03-21 | 0 days | — | $1K–$15K | 86.8 | ↗ filing |
| Robert Wittman | House | BUY | Self | 2017-01-20 | 5 days | — | $1K–$15K 0.2% of NW |
93.1 | ↗ filing |
| Carlos Curbelo | House | BUY | Spouse | 2016-12-30 | 11 days | — | $1K–$15K | 93.1 | ↗ filing |
| David McKinley | House | BUY | Self | 2016-12-27 | 7 days | — | $1K–$15K | 59.5 | ↗ filing |
| David McKinley | House | BUY | Joint | 2016-12-21 | 13 days | — | $15K–$50K | 96.4 | ↗ filing |
| Thomas Rooney | House | BUY | Self | 2016-11-02 | 30 days | — | $1K–$15K | 22.3 | ↗ filing |
| Thomas Rooney | House | BUY | Self | 2016-09-01 | 30 days | — | $1K–$15K | 40.4 | ↗ filing |
| Frank LoBiondo | House | SELL | Self | 2016-06-13 | 37 days | — | $1K–$15K | 75.9 | ↗ filing |
| Thomas Rooney | House | BUY | Self | 2016-06-01 | 30 days | — | $1K–$15K | 75.9 | ↗ filing |
| Thomas MacArthur | House | SELL | Self | 2015-01-27 | 5 days | — | $1K–$15K | 75.9 | ↗ filing |
| Richard Hanna | House | BUY | Self | 2014-05-02 | 38 days | — | $1K–$15K | 40.4 | ↗ filing |
| Richard Hanna | House | BUY | Self | 2014-04-29 | 16 days | — | $1K–$15K | 75.9 | ↗ filing |
| Pete Sessions | House | SELL | Spouse | 2013-04-16 | 0 days | — | $1K–$15K 0.2% of NW |
98.8 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in BDX — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
8
Congress trades with insider convergence
19
…with insider divergence
61
Insider open-market trades
Of the congressional trades in BDX, 8 coincided with corporate insiders moving the same way within 60 days, and 19 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-26 | Feld Michael | C-suite | SELL 10b5-1 | $15K | ↗ EDGAR |
| 2026-09-28 | Feld Michael | C-suite | SELL 10b5-1 | $14K | ↗ EDGAR |
| 2026-08-26 | Feld Michael | C-suite | SELL 10b5-1 | $31K | ↗ EDGAR |
| 2026-08-13 | Polen Thomas E Jr | C-suite | SELL 10b5-1 | $768K | ↗ EDGAR |
| 2026-08-11 | Goette Roland | C-suite | SELL | $441K | ↗ EDGAR |
| 2026-07-27 | Feld Michael | C-suite | SELL 10b5-1 | $12K | ↗ EDGAR |
| 2026-06-26 | Feld Michael | C-suite | SELL 10b5-1 | $11K | ↗ EDGAR |
| 2026-06-24 | Garrison Michael David | Other | SELL 10b5-1 | $160K | ↗ EDGAR |
| 2026-06-10 | Garrison Michael David | Other | SELL 10b5-1 | $167K | ↗ EDGAR |
| 2026-06-01 | Polen Thomas E Jr | C-suite | SELL 10b5-1 | $405K | ↗ EDGAR |
| 2026-05-26 | Feld Michael | C-suite | SELL 10b5-1 | $11K | ↗ EDGAR |
| 2026-04-27 | Feld Michael | C-suite | SELL 10b5-1 | $11K | ↗ EDGAR |
| 2026-03-26 | Feld Michael | C-suite | SELL 10b5-1 | $12K | ↗ EDGAR |
| 2026-02-26 | Feld Michael | C-suite | SELL 10b5-1 | $14K | ↗ EDGAR |
| 2026-02-18 | SCOTT BERTRAM L | Director | SELL | $174K | ↗ EDGAR |
| 2026-01-26 | Feld Michael | Other | SELL 10b5-1 | $15K | ↗ EDGAR |
| 2026-01-15 | Garrison Michael David | Other | SELL 10b5-1 | $125K | ↗ EDGAR |
| 2026-01-15 | Garrison Michael David | Other | SELL 10b5-1 | $209K | ↗ EDGAR |
| 2025-12-26 | Feld Michael | Other | SELL 10b5-1 | $15K | ↗ EDGAR |
| 2025-12-17 | Garrison Michael David | Other | SELL 10b5-1 | $123K | ↗ EDGAR |
| 2025-12-01 | Feld Michael | Other | SELL 10b5-1 | $15K | ↗ EDGAR |
| 2025-11-07 | SCOTT BERTRAM L | Director | SELL | $38K | ↗ EDGAR |
| 2025-10-27 | Feld Michael | C-suite | SELL 10b5-1 | $11K | ↗ EDGAR |
| 2025-09-26 | Feld Michael | C-suite | SELL 10b5-1 | $10K | ↗ EDGAR |
| 2025-09-10 | Fraser Claire | Director | SELL | $172K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-26 | Feld Michael C-suite 10b5-1 | SELL | $15K |
| ◆ insider | 2026-09-28 | Feld Michael C-suite 10b5-1 | SELL | $14K |
| Congress | 2026-09-11 | Rohit Khanna | BUY | $1K–$15K |
| ◆ insider | 2026-08-26 | Feld Michael C-suite 10b5-1 | SELL | $31K |
| ◆ insider | 2026-08-13 | Polen Thomas E Jr C-suite 10b5-1 | SELL | $768K |
| ◆ insider | 2026-08-11 | Goette Roland C-suite | SELL | $441K |
| ◆ insider | 2026-07-27 | Feld Michael C-suite 10b5-1 | SELL | $12K |
| ◆ insider | 2026-06-26 | Feld Michael C-suite 10b5-1 | SELL | $11K |
| ◆ insider | 2026-06-24 | Garrison Michael David Other 10b5-1 | SELL | $160K |
| ◆ insider | 2026-06-10 | Garrison Michael David Other 10b5-1 | SELL | $167K |
| ◆ insider | 2026-06-01 | Polen Thomas E Jr C-suite 10b5-1 | SELL | $405K |
| ◆ insider | 2026-05-26 | Feld Michael C-suite 10b5-1 | SELL | $11K |
| Congress | 2026-05-21 | Thomas Kean | SELL | $1K–$15K |
| ◆ insider | 2026-04-27 | Feld Michael C-suite 10b5-1 | SELL | $11K |
| Congress | 2026-03-27 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2026-03-26 | Feld Michael C-suite 10b5-1 | SELL | $12K |
| Congress | 2026-03-17 | Kevin Hern | SELL | $15K–$50K |
| ◆ insider | 2026-02-26 | Feld Michael C-suite 10b5-1 | SELL | $14K |
| ◆ insider | 2026-02-18 | SCOTT BERTRAM L Director | SELL | $174K |
| ◆ insider | 2026-01-26 | Feld Michael Other 10b5-1 | SELL | $15K |
| ◆ insider | 2026-01-15 | Garrison Michael David Other 10b5-1 | SELL | $125K |
| ◆ insider | 2026-01-15 | Garrison Michael David Other 10b5-1 | SELL | $209K |
| ◆ insider | 2025-12-26 | Feld Michael Other 10b5-1 | SELL | $15K |
| ◆ insider | 2025-12-17 | Garrison Michael David Other 10b5-1 | SELL | $123K |
FAQ Common questions
How much has Congress traded BDX?
39 disclosed buys and 33 sells of BDX (Becton Dickinson & Co.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade BDX?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.